TOCILIZUMAB treatment in COVID-19

Tocilizumab (TCZ) is a humanized monoclonal antibody against the interleukin-6 (IL- 6) receptor. It is found that IL‐6 is one of the most important cytokines involved in COVID‐19‐induced cytokine storms and its higher levels are found in critically ill patients with COVID-19. Real‐life data about the effect of TCZ on the inflammatory activity in COVID‐19 patients as well as its side effects are still missing